Article Versions Notes

Lynch KN, Liu JF, Kesten N, Chow K-H, Shetty A, He R, Afreen MF, Yuan L, Matulonis UA, Growdon WB, et al. Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions. Cancers. 2021; 13(9):2195. https://doi.org/10.3390/cancers13092195

Lynch, Katherine N., Joyce F. Liu, Nikolas Kesten, Kin-Hoe Chow, Aniket Shetty, Ruiyang He, Mosammat Faria Afreen, Liping Yuan, Ursula A. Matulonis, Whitfield B. Growdon, and et al. 2021. "Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions" Cancers 13, no. 9: 2195. https://doi.org/10.3390/cancers13092195

Lynch, K. N., Liu, J. F., Kesten, N., Chow, K.-H., Shetty, A., He, R., Afreen, M. F., Yuan, L., Matulonis, U. A., Growdon, W. B., Muto, M. G., Horowitz, N. S., Feltmate, C. M., Worley, M. J., Jr., Berkowitz, R. S., Crum, C. P., Rueda, B. R., & Hill, S. J. (2021). Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions. Cancers, 13(9), 2195. https://doi.org/10.3390/cancers13092195